alendronate has been researched along with Recrudescence in 15 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
| Excerpt | Relevance | Reference |
|---|---|---|
| "There is high evidence for secondary prevention of fractures, including hip fracture, with alendronate treatment, but alendronate's efficacy to prevent hip fractures in the oldest-old (≥80 years old), the population with the highest fracture risk, has not been studied." | 3.85 | Hip fracture risk and safety with alendronate treatment in the oldest-old. ( Axelsson, KF; Johansson, H; Lorentzon, M; Lundh, D; Wallander, M, 2017) |
| " We report on a 35-year-old female who was diagnosed with TRAPS, after finding the V95M mutation on the TNFRSF1A gene; who was treated in order with etanercept, anakinra, and canakinumab (150 mg/every 8 weeks by subcutaneous injection, then increased to 150 mg every 4 weeks); and who started therapy with oral alendronate (70 mg/weekly) to control her osteoporosis." | 3.81 | Tumor necrosis factor receptor-associated periodic syndrome managed with the couple canakinumab-alendronate. ( Cantarini, L; Frediani, B; Iannone, F; Lopalco, G; Rigante, D; Vitale, A, 2015) |
| "Disodium alendronate can cause intraocular inflammation (panuveitis and anterior uveitis), which requires discontinuing the treatment." | 3.72 | [Biphosphonates and intraocular inflammation]. ( Asensio Sánchez, VM; Botella Oltra, G; Carrasco, E, 2004) |
| "There are very few cases of pathological fracture induced by pancreatitis that affect the vertebrae." | 1.37 | Pathological fracture due to vertebral osteonecrosis associated with pancreatitis. ( Baba, T; Kaneko, H; Shitoto, K; Yoshioka, C, 2011) |
| "When there is osteopenia in the radiographs, the condition is called transient osteoporosis." | 1.36 | Migrating bone marrow edema syndrome: a cause of recurring knee pain. ( Suresh, SS, 2010) |
| "Histopathologic analysis revealed a parathyroid adenoma." | 1.36 | Primary hyperparathyroidism with classic and severe skeletal involvement. ( Paz-Pacheco, E; Sandoval, MA, 2010) |
| "Etidronate treatment at 200 mg/day resulted in the improvement of bone metabolism markers and bone scintigraphy findings." | 1.32 | Two cases of monostotic Paget's disease: effects of bisphosphonate. ( Aoki, N; Harada, T; Hoshiro, M; Iwai, H; Miyatake, T; Nishimura, A; Ohno, Y, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (40.00) | 29.6817 |
| 2010's | 9 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Axelsson, KF | 1 |
| Wallander, M | 1 |
| Johansson, H | 1 |
| Lundh, D | 1 |
| Lorentzon, M | 1 |
| Lopalco, G | 1 |
| Rigante, D | 1 |
| Vitale, A | 1 |
| Frediani, B | 1 |
| Iannone, F | 1 |
| Cantarini, L | 1 |
| Arrabal-Martín, M | 2 |
| González-Torres, S | 2 |
| Cano-García, MD | 1 |
| De Haro-Muñoz, T | 2 |
| Abad-Menor, F | 1 |
| Arrabal-Polo, MÁ | 2 |
| Cózar-Olmo, JM | 1 |
| Chen, JS | 1 |
| Chen, PM | 1 |
| Lin, CY | 1 |
| Chen, RF | 1 |
| Lee, PY | 1 |
| Baba, T | 1 |
| Shitoto, K | 1 |
| Yoshioka, C | 1 |
| Kaneko, H | 1 |
| Naranjo, A | 1 |
| Ojeda-Bruno, S | 1 |
| Francisco-Hernández, F | 1 |
| Erausquin, C | 1 |
| Rúa-Figueroa, I | 1 |
| Rodríguez-Lozano, C | 1 |
| Suresh, SS | 1 |
| Sandoval, MA | 1 |
| Paz-Pacheco, E | 1 |
| Arias-Santiago, S | 1 |
| Lopez-Ruiz, A | 1 |
| Orgaz-Molina, J | 1 |
| Zuluaga-Gomez, A | 1 |
| Hoshiro, M | 1 |
| Harada, T | 1 |
| Iwai, H | 1 |
| Miyatake, T | 1 |
| Nishimura, A | 1 |
| Ohno, Y | 1 |
| Aoki, N | 1 |
| Asensio Sánchez, VM | 1 |
| Botella Oltra, G | 1 |
| Carrasco, E | 1 |
| Chun, CS | 1 |
| Kamel, HK | 1 |
| Bida, A | 1 |
| Montagnini, M | 1 |
| Segal, E | 1 |
| Zinnman, C | 1 |
| Raz, B | 1 |
| Tamir, A | 1 |
| Gurevich, B | 1 |
| Siebzehner, MI | 1 |
| Ish-Shalom, S | 1 |
| Mikhail, N | 1 |
| Cope, D | 1 |
1 review available for alendronate and Recrudescence
| Article | Year |
|---|---|
Chronic recurrent multifocal osteomyelitis of the spine and mandible: case report and review of the literature.
Topics: Alendronate; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Child, Preschool; Chron | 2004 |
14 other studies available for alendronate and Recrudescence
| Article | Year |
|---|---|
Hip fracture risk and safety with alendronate treatment in the oldest-old.
Topics: Aged, 80 and over; Alendronate; Body Mass Index; Bone Density Conservation Agents; Case-Control Stud | 2017 |
Tumor necrosis factor receptor-associated periodic syndrome managed with the couple canakinumab-alendronate.
Topics: Adult; Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Drug Therapy, Combina | 2015 |
Urine Calcium and Bone Mineral Density in Calcium Stone-Forming Patients Treated with Alendronate and Hydrochlorothiazide.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Calcium; Diuretics; Female; Follow-Up S | 2016 |
Beneficial effects of bipolar hemiarthroplasty replacement and fosamax in the retrospective cohort study of refracture and mortality of hip fractured patients.
Topics: Aged; Alendronate; Arthroplasty, Replacement, Hip; Bone Density; Bone Density Conservation Agents; C | 2016 |
Pathological fracture due to vertebral osteonecrosis associated with pancreatitis.
Topics: Alendronate; Bone and Bones; Bone Density Conservation Agents; Disease Progression; Fat Necrosis; Fr | 2011 |
[Application of guidelines for secondary prevention of fracture and the FRAX index in patients with fragility fracture].
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservatio | 2011 |
Migrating bone marrow edema syndrome: a cause of recurring knee pain.
Topics: Alendronate; Anti-Inflammatory Agents, Non-Steroidal; Bone Density; Bone Density Conservation Agents | 2010 |
Primary hyperparathyroidism with classic and severe skeletal involvement.
Topics: Adenoma; Alendronate; Calcitriol; Calcium Carbonate; Female; Follow-Up Studies; Fractures, Spontaneo | 2010 |
Effects of aminobisphosphonates and thiazides in patients with osteopenia/osteoporosis, hypercalciuria, and recurring renal calcium lithiasis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcium; Fema | 2013 |
Two cases of monostotic Paget's disease: effects of bisphosphonate.
Topics: Aged; Alendronate; Alkaline Phosphatase; Biomarkers; Bone and Bones; Bone Remodeling; Diphosphonates | 2003 |
[Biphosphonates and intraocular inflammation].
Topics: Aged; Alendronate; Female; Humans; Panuveitis; Recurrence; Uveitis, Anterior; Visual Acuity | 2004 |
Secondary prevention of hip fractures in veterans: can we do better?
Topics: Aged; Aged, 80 and over; Alendronate; Calcium; Drug Utilization; Geriatrics; Great Lakes Region; Hip | 2004 |
Second hip fracture in elderly hip fracture patients: cost and effectiveness of fracture prevention treatment.
Topics: Aged; Alendronate; Calcium; Cholecalciferol; Costs and Cost Analysis; Hip Fractures; Humans; Osteopo | 2005 |
Alendronate and vertebral fracture risk.
Topics: Alendronate; Bone Density; Data Interpretation, Statistical; Female; Femur Neck; Hip Fractures; Huma | 2005 |